Terms: = Colorectal cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
223 results:
1. Sulfated Polyhydroxysteroid Glycosides from the Sea of Okhotsk Starfish
Kicha AA; Tolkanov DK; Malyarenko TV; Malyarenko OS; Kuzmich AS; Kalinovsky AI; Popov RS; Stonik VA; Ivanchina NV; Dmitrenok PS
Mar Drugs; 2024 Jun; 22(7):. PubMed ID: 39057403
[TBL] [Abstract] [Full Text] [Related]
2. Role of mek1 and DIAPH3 expression in colorectal adenoma-carcinoma sequence.
Foda AAM; El-Hawary AK; Elnaghi K; Eldehna WM; Enan ET
Tumour Biol; 2024; 46(1):1-11. PubMed ID: 38728194
[TBL] [Abstract] [Full Text] [Related]
3. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
[TBL] [Abstract] [Full Text] [Related]
4. The EIF3H-HAX1 axis increases RAF-MEK-ERK signaling activity to promote colorectal cancer progression.
Jin H; Huang X; Pan Q; Ma N; Xie X; Wei Y; Yu F; Wen W; Zhang B; Zhang P; Chen X; Wang J; Liu RY; Lin J; Meng X; Lee MH
Nat Commun; 2024 Mar; 15(1):2551. PubMed ID: 38514606
[TBL] [Abstract] [Full Text] [Related]
5. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction.
Weidner P; Saar D; Söhn M; Schroeder T; Yu Y; Zöllner FG; Ponelies N; Zhou X; Zwicky A; Rohrbacher FN; Pattabiraman VR; Tanriver M; Bauer A; Ahmed H; Ametamey SM; Riffel P; Seger R; Bode JW; Wade RC; Ebert MPA; Kragelund BB; Burgermeister E
Cancer Lett; 2024 Apr; 588():216783. PubMed ID: 38462034
[TBL] [Abstract] [Full Text] [Related]
6. Activation of CHPF by transcription factor NFIC promotes NLRP3 activation during the progression of colorectal cancer.
Wu J; Wang M; Zhang Y; Liu G; Xing Y
Funct Integr Genomics; 2024 Jan; 24(1):20. PubMed ID: 38267731
[TBL] [Abstract] [Full Text] [Related]
7. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
8. Nuclear pore protein POM121 regulates subcellular localization and transcriptional activity of PPARγ.
Yu Y; Farooq MS; Eberhart Meessen S; Jiang Y; Kato D; Zhan T; Weiss C; Seger R; Kang W; Zhang X; Yu J; Ebert MPA; Burgermeister E
Cell Death Dis; 2024 Jan; 15(1):7. PubMed ID: 38177114
[TBL] [Abstract] [Full Text] [Related]
9. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo.
Najumudeen AK; Fey SK; Millett LM; Ford CA; Gilroy K; Gunduz N; Ridgway RA; Anderson E; Strathdee D; Clark W; Nixon C; Morton JP; Campbell AD; Sansom OJ
Nat Commun; 2024 Jan; 15(1):100. PubMed ID: 38168062
[TBL] [Abstract] [Full Text] [Related]
10. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
[TBL] [Abstract] [Full Text] [Related]
11. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
12. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (mek162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic colorectal cancer.
Van Cutsem E; Yaeger R; Delord JP; Tabernero J; Siu LL; Ducreux M; Siena S; Elez E; Kasper S; Zander T; Steeghs N; Murphy D; Edwards M; Wainberg ZA
Oncologist; 2023 Dec; 28(12):e1209-e1218. PubMed ID: 37597246
[TBL] [Abstract] [Full Text] [Related]
13. Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.
Lee CL; Cremona M; Farrelly A; Workman JA; Kennedy S; Aslam R; Carr A; Madden S; O'Neill B; Hennessy BT; Toomey S
Cancer Biol Ther; 2023 Dec; 24(1):2223388. PubMed ID: 37326340
[TBL] [Abstract] [Full Text] [Related]
14. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic colorectal cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M; Tabernero J; Grothey A; Arnold D; O'Dwyer PJ; Gilberg F; Abbas A; Thakur MD; Prizant H; Irahara N; Tahiri A; Schmoll HJ; Van Cutsem E; de Gramont A
Eur J Cancer; 2023 May; 184():137-150. PubMed ID: 36921494
[TBL] [Abstract] [Full Text] [Related]
16. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and mek1/2.
Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
[TBL] [Abstract] [Full Text] [Related]
17. Melatonin-Assisted Cisplatin Suppresses Urinary Bladder cancer Cell Proliferation and Growth through Inhibiting PrP
Yang CC; Chuang FC; Chang CL; Huang CR; Chen HH; Yip HK; Chen YT
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834767
[TBL] [Abstract] [Full Text] [Related]
18. The association of blood ctDNA levels to mutations of marker genes in colorectal cancer.
Bai F; Du Q; Zou Q; Xu L; Dong W; Lv X; Han X; Zhou H; Zhang C; Lu T
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1782. PubMed ID: 36746394
[TBL] [Abstract] [Full Text] [Related]
19. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract] [Full Text] [Related]
20. Driver and targetable alterations in Chinese patients with small bowel carcinoma.
Li J; Li X; Dong N; Yan S; Jing C; Ma T; Li W; Zhang C; Cai Y; Deng W
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6139-6150. PubMed ID: 36680582
[TBL] [Abstract] [Full Text] [Related]
[Next]
